In addition to the shares sold in the underwritten public offering, Lexicon granted the underwriters a 30-day option to purchase up to an additional 4,800,000 shares of common stock at the public ...
The company also stands to gain from recent regulatory FDA guidance aimed at streamlining the development of non-opioid painkillers, Jefferies analysts suggested.
Lexicon Pharmaceuticals shares were 21% lower, at $1.14, after the company priced its underwritten public offering of 32 million shares at $1.30 a share. All of the shares are being offered by Lexicon ...
As of Friday, January 30, Lexicon Pharmaceuticals, Inc.’s LXRX share price has dipped by 16.32%, which has investors ...
Jefferies and Piper Sandler are acting as joint book-running managers for the proposed offering.
Lexicon Pharmaceuticals, Inc. is downgraded to Hold due to repeated FDA rejections of ZYNQUISTA for T1D and catalysts. Read more on LXRX stock here.
Lexicon Pharma (LXRX) prices 32M-share offering at $1.30 and $41M+ private placement to fund R&D and working capital—get the key details now.
No objections raised by FDA to advancement of pilavapadin into Phase 3 development utilizing two-arm registrational studies of 10 mg daily dose compared to placebo - ...
Lexicon Pharmaceuticals won't take no for an answer. The Texas pharma—convinced of the value of its diabetes candidate sotagliflozin—has clapped back at its latest rejection from the FDA, asking to be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results